Baseline characteristics, crude survival, and prognosis
| . | N (%) . | OS . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| 5-y (95% CI) . | 10-y (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | ||
| All patients | 593 | 89.4 (86.8-92.1) | 74.4 (70.6-79.1) | |||||
| Age group, y | <.001 | |||||||
| <60 | 282 (47.6) | 96.9 (94.8-99.0) | 87.9 (83.2-92.9) | Ref | Ref | |||
| 60-70 | 152 (25.6) | 85.1 (79.3-91.2) | 74.2 (66.6-82.7) | 2.34 (1.44-3.77) | .001 | 2.36 (1.46-3.82) | <.001 | |
| ≥70 | 159 (26.8) | 81.2 (75.1-87.9) | 53.3 (44.6-63.8) | 5.15 (3.37-7.85) | <.001 | 4.93 (3.22-7.53) | <.001 | |
| Sex | .315 | |||||||
| Male | 262 (44.2) | 88.8 (84.0-93.0) | 70.8 (64.1-78.2) | Ref | ||||
| Female | 331 (55.8) | 89.9 (86.6-93.4) | 77.4 (72.3-83.0) | 0.84 (0.60-1.18) | .315 | |||
| Stage | ||||||||
| I | 388 (65.4) | 90.8 (87.7-93.9) | 78.3 (73.4-83.6) | .007 | Ref | Ref | ||
| II | 38 (6.4) | 85.9 (75.2-98.2) | 71.6 (57.2-89.6) | 1.89 (1.03-3.50) | .041 | 1.78 (0.96-3.31) | .067 | |
| III-IV | 167 (28.2) | 87.3 (82.2-92.6) | 68.3 (60.6-77.0) | 1.67 (1.17-2.39) | .005 | 1.70 (1.18-2.43) | .004 | |
| MMS | ||||||||
| Absent | 530 (89.4) | 90.3 (87.7-93.1) | 75.1 (70.7-79.8) | .032 | Ref | .034 | ||
| Present | 63 (10.6) | 81.9 (72.8-92.2) | 71.3 (60.6-83.9) | 1.64 (1.04-2.59) | ||||
| Primary site | .059 | |||||||
| Gastric | 120 (20.2) | 94.5 (90.3-98.9) | 79.6 (70.6-89.8) | Ref | ||||
| Skin | 104 (17.5) | 96.5 (92.6-100) | 81.9 (73.3-91.4) | 0.59 (0.30-1.16) | .126 | |||
| Lung | 82 (13.8) | 88.5 (81.6-95.9) | 66.9 (55.4-80.8) | 1.14 (0.85-1.53) | .382 | |||
| Orbit | 77 (13.0) | 79.0 (69.8-89.4) | 67.3 (56.2-80.7) | 1.12 (0.92-1.37) | .240 | |||
| BM involvement∗ | .023 | |||||||
| No | 285 (48.1) | 90.5 (86.9-94.2) | 78.4 (72.8-84.5) | Ref | ||||
| Yes | 36 (6.1) | 85.5 (74.5-98.1) | 55.9 (39.7-78.6) | 2.14 (1.23-3.72) | .007 | |||
| ECOG PS† | <.001 | |||||||
| 0-1 | 582 (98.1) | 90.4 (87.9-93.0) | 75.3 (71.1-79.8) | Ref | Ref | |||
| >1 | 11 (1.9) | 40.9 (19.4-86.3) | - | 7.93 (3.85-16.37) | <.001 | 7.02 (3.35-14.73) | <.001 | |
| LDH | .285 | |||||||
| Normal | 562 (94.8) | 90.0 (87.4-92.7) | 74.4 (70.1-79.0) | Ref | ||||
| Elevated | 31 (5.2) | 79.4 (66.0-95.5) | 66.0 (49.6-87.9) | 1.44 (0.73-2.84) | .287 | |||
| MALT-IPI risk | <.001 | |||||||
| Low | 296 (49.9) | 93.5 (90.8-96.8) | 85.3 (80.5-90.5) | Ref | ||||
| Intermediate | 239 (40.3) | 87.9 (83.7-92.4) | 69.0 (62.1-76.6) | 2.51 (1.69-3.72) | <.001 | |||
| High | 58 (9.8) | 76.7 (66.3-88.7) | 48.8 (35.8-66.4) | 4.90 (3.01-7.98) | <.001 | |||
| . | N (%) . | OS . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|---|---|
| 5-y (95% CI) . | 10-y (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | ||
| All patients | 593 | 89.4 (86.8-92.1) | 74.4 (70.6-79.1) | |||||
| Age group, y | <.001 | |||||||
| <60 | 282 (47.6) | 96.9 (94.8-99.0) | 87.9 (83.2-92.9) | Ref | Ref | |||
| 60-70 | 152 (25.6) | 85.1 (79.3-91.2) | 74.2 (66.6-82.7) | 2.34 (1.44-3.77) | .001 | 2.36 (1.46-3.82) | <.001 | |
| ≥70 | 159 (26.8) | 81.2 (75.1-87.9) | 53.3 (44.6-63.8) | 5.15 (3.37-7.85) | <.001 | 4.93 (3.22-7.53) | <.001 | |
| Sex | .315 | |||||||
| Male | 262 (44.2) | 88.8 (84.0-93.0) | 70.8 (64.1-78.2) | Ref | ||||
| Female | 331 (55.8) | 89.9 (86.6-93.4) | 77.4 (72.3-83.0) | 0.84 (0.60-1.18) | .315 | |||
| Stage | ||||||||
| I | 388 (65.4) | 90.8 (87.7-93.9) | 78.3 (73.4-83.6) | .007 | Ref | Ref | ||
| II | 38 (6.4) | 85.9 (75.2-98.2) | 71.6 (57.2-89.6) | 1.89 (1.03-3.50) | .041 | 1.78 (0.96-3.31) | .067 | |
| III-IV | 167 (28.2) | 87.3 (82.2-92.6) | 68.3 (60.6-77.0) | 1.67 (1.17-2.39) | .005 | 1.70 (1.18-2.43) | .004 | |
| MMS | ||||||||
| Absent | 530 (89.4) | 90.3 (87.7-93.1) | 75.1 (70.7-79.8) | .032 | Ref | .034 | ||
| Present | 63 (10.6) | 81.9 (72.8-92.2) | 71.3 (60.6-83.9) | 1.64 (1.04-2.59) | ||||
| Primary site | .059 | |||||||
| Gastric | 120 (20.2) | 94.5 (90.3-98.9) | 79.6 (70.6-89.8) | Ref | ||||
| Skin | 104 (17.5) | 96.5 (92.6-100) | 81.9 (73.3-91.4) | 0.59 (0.30-1.16) | .126 | |||
| Lung | 82 (13.8) | 88.5 (81.6-95.9) | 66.9 (55.4-80.8) | 1.14 (0.85-1.53) | .382 | |||
| Orbit | 77 (13.0) | 79.0 (69.8-89.4) | 67.3 (56.2-80.7) | 1.12 (0.92-1.37) | .240 | |||
| BM involvement∗ | .023 | |||||||
| No | 285 (48.1) | 90.5 (86.9-94.2) | 78.4 (72.8-84.5) | Ref | ||||
| Yes | 36 (6.1) | 85.5 (74.5-98.1) | 55.9 (39.7-78.6) | 2.14 (1.23-3.72) | .007 | |||
| ECOG PS† | <.001 | |||||||
| 0-1 | 582 (98.1) | 90.4 (87.9-93.0) | 75.3 (71.1-79.8) | Ref | Ref | |||
| >1 | 11 (1.9) | 40.9 (19.4-86.3) | - | 7.93 (3.85-16.37) | <.001 | 7.02 (3.35-14.73) | <.001 | |
| LDH | .285 | |||||||
| Normal | 562 (94.8) | 90.0 (87.4-92.7) | 74.4 (70.1-79.0) | Ref | ||||
| Elevated | 31 (5.2) | 79.4 (66.0-95.5) | 66.0 (49.6-87.9) | 1.44 (0.73-2.84) | .287 | |||
| MALT-IPI risk | <.001 | |||||||
| Low | 296 (49.9) | 93.5 (90.8-96.8) | 85.3 (80.5-90.5) | Ref | ||||
| Intermediate | 239 (40.3) | 87.9 (83.7-92.4) | 69.0 (62.1-76.6) | 2.51 (1.69-3.72) | <.001 | |||
| High | 58 (9.8) | 76.7 (66.3-88.7) | 48.8 (35.8-66.4) | 4.90 (3.01-7.98) | <.001 | |||